(pan-i-tu-mu-mab) ,


(trade name)


Therapeutic: antineoplastics
Pharmacologic: monoclonal antibodies
Pregnancy Category: C


Treatment of metastatic colorectal cancer that expresses EGFR (epidermal growth factor receptor) and has failed conventional treatments (to be used as monotherapy).


genetic implication Binds to EGFR resulting in inactivation of kinases that regulate proliferation and transformation.

Therapeutic effects

Decreased progression of colorectal cancer.


Absorption: IV administration results in complete bioavailability.
Distribution: Monoclonal antibodies cross the placenta and enter breast milk.
Metabolism and Excretion: Unknown.
Half-life: 7.5 days.

Time/action profile

IVunknownend of infusionunknown


Contraindicated in: Concurrent leucovorin;genetic implication Patients whose tumors have KRAS mutations in codon 12 or 13 (not effective); Obstetric / Lactation: Pregnancy or lactation.
Use Cautiously in: Pediatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • fatigue (most frequent)

Ear, Eye, Nose, Throat

  • ocular toxicity (life-threatening)
  • eyelash growth


  • pulmonary fibrosis (life-threatening)
  • cough (most frequent)


  • abdominal pain (most frequent)
  • constipation (most frequent)
  • diarrhea (most frequent)
  • nausea (most frequent)
  • vomiting (most frequent)
  • stomatitis


  • necrotizing fasciitis (life-threatening)
  • paromychia (most frequent)
  • abscesses
  • dry skin
  • erythema
  • photosensitivity
  • pruritis
  • rash
  • skin fissures

Fluid and Electrolyte

  • edema (most frequent)
  • hypocalcemia
  • hypomagnesemia (most frequent)


  • infusion reactions (life-threatening)
  • sepsis (life-threatening)


Drug-Drug interaction

None noted.


Intravenous (Adults) 6 mg/kg as a 60-min infusion every 14 days; ↓ infusion rates and dose modifications are recommended for infusion reactions and other serious toxicities.


Solution for IV administration (requires dilution): 20 mg/mL

Nursing implications

Nursing assessment

  • Assess for dermatologic toxicity (dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, skin fissures). If severe, may lead to infection (sepsis, septic death, abscesses requiring incision and drainage). With severe reactions, withhold panitumumab and monitor for inflammatory or infectious sequelae.
  • Monitor for severe infusion reactions (anaphylactic reaction, bronchospasm, fever, chills, hypotension). If severe reaction occurs, stop panitumumab; may require permanent discontinuation.
  • Assess for pulmonary fibrosis (cough, wheezing, exertional dyspnea, interstitial lung disease, pneumonitis, lung infiltrates). Permanently discontinue panitumumab if these signs occur.
  • Monitor for diarrhea during therapy.
  • Lab Test Considerations: Monitor electrolyte levels periodically during and for 8 wk after completion of therapy. May cause hypomagnesemia and hypocalcemia.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Adverse Reactions)
Impaired gas exchange (Adverse Reactions)


  • Intermittent Infusion: Diluent: Withdraw necessary amount of panitumumab. Dilute to a volume of 100 mL with 0.9% NaCl; dilute doses >1000 mg with 150 mL.Concentration: 10 mg/mL. Mix by inverting gently; do not shake. Administer via infusion pump using a low-protein binding 0.2 mcg or 0.22 mcg in-line filter. Solution is colorless and may contain a small amount of visible translucent to white, amorphous, proteinaceous particles. Do not administer solutions that are discolored or contain particulate matter. Store in refrigerator; do not freeze. Use diluted solution within 6 hr of preparation if stored at room temperature or within 24 hr if refrigerated.
  • Rate: Administer over 60 min every 14 days. Administer doses >1000 mg over 90 min.
    • If mild to moderate infusion reaction (Grade 1 or 2) occurs decrease infusion rate by 50%. If severe reaction (Grade 3 or 4) occurs, immediately and permanently discontinue panitumumab.
    • If severe dermatologic toxicities (Grade 3 or higher) or those considered intolerable occur, withhold panitumumab. If toxicity does not improve to ≤ grade 2 within 1 mo, discontinue permanently. If toxicity improves to ≤ grade 2 and patient improves symptomatically after withholding no more than 2 doses, resume therapy at 50% dose. If toxicities recur, permanently discontinue panitumumab. If toxicities do not recur, increase subsequent doses in 25% increments of the original dose until recommended dose of 6 mg/kg is reached.
  • Y-Site Incompatibility: Flush line before and after administration with 0.9% NaCl. Do not mix with other medications or solutions.

Patient/Family Teaching

  • Explain purpose of panitumumab to patient.
  • May cause photosensitivity. Caution patient to wear sunscreen and hats and to limit sun exposure.
  • Advise patient to notify health care professional if signs and symptoms of dermatologic toxicity, infusion reactions, pulmonary fibrosis, or ocular changes occur.
  • Advise patient that panitumumab may cause fertility impairment and may have teratogenic effects. Caution women of childbearing yr to use contraception during and for at least 6 mo after the last dose and not to breast feed during and for at least 2 mo after the last dose of panitumumab. Encourage women who become pregnant to enroll in Amgen’s Pregnancy Surveillance Program by calling 1-800-772-6436.
  • Emphasize the need for periodic blood tests to monitor electrolyte levels.

Evaluation/Desired Outcomes

  • Decreased progression of colorectal cancer.
Drug Guide, © 2015 Farlex and Partners
Mentioned in ?
References in periodicals archive ?
Vectibix (panitumumab) sales increased 13% driven by higher unit demand.
She played key roles at Amgen in the approval of Vectibix and Kepivance.
Panitumumab (Vectibix) is a recombinant fully human monoclonal antibody approved in 2006 for EGFR-expressing mCRC after failing conventional chemotherapy regimens.
Soft but Reliable Growth: Growth of a number of established products, XGEVA (bone metastases), Prolia (osteoporosis), Nplate (thrombocytopenia), Vectibix (metastatic colorectal cancer), and Sensipar (secondary hyperparathyroidism), should help to offset some of the risk of anticipated branded and biosimilar competition against Neulasta and Epogen and existing competition against Neupogen.
* When treatment with panitumumab (Vectibix) or cetuximab (Erbitux) was limited to patients with metastatic colorectal cancer whose KRAS gene was not mutated, an annual savings of $604 million among all patients was achieved.
(Vectibix) Approved by the FDA in 2006 for the treatment of patients with EGFR-expressing, metastatic colorectal cancer with disease progression.
The second drug based on the same research is Vectibix. This EGFR blocker is approved for the treatment of metastatic colorectal cancer.
There are 2 EGFR-targeted monoclonal antibody therapies used in colorectal cancer: cetuximab and panitumumab (Vectibix, Amgen, Thousand Oaks, California).
US-based biotechnology company Amgen (NASDAQ: AMGN) has entered into a definitive agreement with UK-based drugmaker GSK to reacquire all of its remaining rights to Prolia (denosumab), Xgeva (denosumab) and Vectibix (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world, the company said.
[15] K-ras codon 12 mutation is a good biomarker in stage IV CRC, predicting lack of benefit from the anti-EGFR targeted antibodies cetuximab (Erbitux) and panitumab (Vectibix).